A comparison of mixture cure fraction models to traditional parametric survival models in estimation of the cost-effectiveness of nivolumab for relapsed small cell lung cancer

Joshua A. Rotha Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USACorrespondence[email protected]

Yong Yuanb Global Health Outcomes, Bristol-Myers Squibb, Princeton, NJ, USA

Megan Othusa Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Mark Danesec HEOR, Outcomes Insights, Westlake Village, CA, USA

Samuel Wagnerb Global Health Outcomes, Bristol-Myers Squibb, Princeton, NJ, USA

John R. Penrodb Global Health Outcomes, Bristol-Myers Squibb, Princeton, NJ, USA

Scott D. Ramseya Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Your download is now in progress and you may close this window